Sjogren's SyndromeAEPSSNCT02370225
Aerobic Exercise in Primary Sjögren's Syndrome
A study testing aerobic exercise in people with Sjogren's Syndrome, run by Samira Tatiyama Miyamoto, PhD at 1 site in Brazil.
Trial summary
The purpose of this sudy is to investigate the effects of a regular aerobic exercise on aerobic capacity, fatigue, depression, quality of life, perception of symptoms and disease activity in women with pSS. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Sjogren's Syndrome
- What is being tested?
- aerobic exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteBrazil
- Study dates
- Mar 2015to Mar 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- female gender and age ≤ 65 years-old
- pSS diagnosed according to the American European Consensus Criteria (VITALI et al, 2002)
- corporal mass index < 40.
Who cannot join
- use of beta-blocker therapy;
- severe manifestations on pulmonary, renal, neurologic or musculoskeletal system (from the disease or not);
- limiting or hindering their ability to walking performance
- those who had performed regular physical activity in the 6 weeks before trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Aerobic Exercise on Fatigue in Women With Primary Sjögren's Syndrome: Randomized Controlled Trial
The purpose of this sudy is to investigate the effects of a regular aerobic exercise on aerobic capacity, fatigue, depression, quality of life, perception of symptoms and disease activity in women with pSS.
Read the detailed description
This study is a randomized controlled trial. 45 women with primary Sjögren's syndrome diagnosed according to the American European Consensus Criteria (VITALI et al, 2002) and age ≤ 65 years-old will be included. Patients, in blocks of four, will be allocated to treatment group (TG) or control group (CG) by simple randomization according to drawing lots.
Treatment group (TG): subjects will be submitted to a supervised walking, 3 times a week for 16 weeks, by one physiotherapist and one physical education student who alternated weekly. The heart rate of the patients will be registered with a pulse watch (Polar® A1, Kempele, Finland) at the beginning, in the intermediate time and at the final of effective walking time. The general exertion was rated on the Borg RPE 0-10 (ratings of perceived exertion) scale in the intermediate time and at the final of effective walking time. Each training session will be preceded by a warm-up period, where patients will be instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they will be instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).
The exercise prescription will be based on the heart rate at the anaerobic threshold determined at the initial assessment according previous studies with patients with fibromyalgia (VALIM et al, 2002; VALIM et al, 2003; ASSIS et al, 2006) and Systemic Lupus Erythematosus (CARVALHO et al, 2005), which demonstrated that ventilatory anaerobic threshold oxygen uptake, although used less than VO2max, is also a good physical fitness indicator, and it has the advantage of not being maximum effort dependent. It seems to be more influenced by training than VO2max and represents a safer intensity for exercise, thus decreasing the risk of lesions and constituting an important measure for prescription of exercise. As there is no previous studies using spiroergometric test in pSS and fatigue is very similar to fibromyalgia and lupus patients, we believe pSS performance in treadmill test and training is probably the same. The increment of intensity exercise will be based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
Control group (CG): subjects randomized to control group will not participate of the walking exercise initially, but after completing 16 weeks they will be invited to participate of the training group.
Clinical outcomes:
- Fatigue: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) (WEBSTER et al, 1999; WEBSTER et al, 2003)
- Depression: Beck Depression Inventory (BDI) (BECK et al, 1961; GORESTEIN and ANDRADE, 1996).
- Perception of pSS's symptoms: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) (SEROR et al, 2011, PAGANOTTI et al, 2012; PAGANOTTI et al, 2013).
- Disease activity: EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) (SEROR et al, 2010; SERRANO et al, 2013).
- Quality of life: Medical Outcomes Study 36 (SF-36) (CICONELLI et al, 1999) and World Health Organization Quality of Life Instrument - Abbreviated version (WHOQOL-bref) (The Whoqol Group, 1998; FLERCK et al, 2000).
- All patients will be submitted to interview to evaluate fatigue, depression and perception of pSS's symptoms prior to intervention (T0), after 8 weeks (T1) and after 16 weeks (T2). Quality of life and disease activity will be evaluated prior to intervention (T0) and after 16 weeks (T2). Patient global assessment of response to therapy (PGART) on a 5-point scale (1 _ much better, 2 _ better, 3 _ slightly better, 4 _ no change, and 5 _ worse).
Physical fitness outcomes:
Aerobic capacity will be evaluated by spiroergometric test. A computerized metabolic system is used to analyze the data obtained breath by breath. The following outcomes of physical fitness are obtained: peak oxygen uptake (peak VO2), peak heart rate and maximum heart rate at the anaerobic threshold. Anaerobic threshold are considered the mean value of 2 blinded investigators' independent readings. Considering that patients with pSS do not achieve a maximum effort, the anaerobic threshold is the main measure of aerobic fitness (VALIM et al, 2002; VALIM et al, 2003; ASSIS et al, 2006).
All the patients will be underwent an increasing load protocol on the treadmill, with a maximum duration of 13 minutes (VALIM et al, 2002; FAIRSHTER et al, 1983). Beginning with a warm-up period of 3 minutes at 3 km/h and increasing 1 km/h each minute until 7 km/h, at this moment 2,5% inclination is added until 15% in the 13º minute.
All patients will be evaluated prior to intervention (T0) and after 16 weeks (T2).
Statistics:
An intent-to-treat analysis will be performed, using the last-observation-carried-forward method. A level of significance of P<0.05 (2-tailed tests) will be accepted for the trial. The Kolmogorov-Smirnov test will be used to determine whether data will be normally or non-normally distributed. For normally distributed data, the dependent variables will be analyzed using a 2 per 3 repeated-measures analysis of variance (ANOVA). The independent variables in all analyses is group (TG versus CG; between subjects factors) and time (baseline, 8 weeks, and 16 weeks; within subjects factors). Independent sample t-tests will be used in the between-groups comparison of the change scores at midline and treatment completion, when interaction time x group was significant. A 95% confidence interval (95% CI) will be used. Friedman's test will be used for non-normally distributed variables, as an equivalent of ANOVA. Wilcoxon's signed rank test will be used to analyze the difference between times separated by group when the change score was non-normally distributed. Fisher's exact test and chisquare test will be used to determine differences in rates of improvement between the 2 groups. Pearson's and Spearman's correlation coefficients will be used. Multiple linear regression and chi-square tests will be used to analyze the association between the amount of physical fitness improvement and outcome measures. The agreement between heart rate and ratings of perceived exertion during the training will be analyzed by Intraclass Correlation Coefficient.
- Conditions
- Sjogren's Syndrome
- Being tested
- aerobic exercise
- Keywords
- sjogren's syndrome, aerobic exercise, fatigue
- Medical subject headings
- Sjogren's Syndrome, Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
aerobic exerciseOther
Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).
The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
| Study group | Role | What they receive |
|---|---|---|
| aerobic exercise | Experimental | Subjects were submitted to a supervised walking, 3 times a week for 16 weeks. Receives: Other: aerobic exercise |
| no exercise | No intervention | Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in fatigue at 16 weeks
questionnaires: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) (WEBSTER et al, 1999; WEBSTER et al, 2003)
Measured: baseline and 16 weeks
Secondary outcomes (7)
Change from baseline in aerobic capacity at 16 weeks
Aerobic capacity has been evaluated by spiroergometric test. A computerized metabolic system is used to analyze the data obtained breath by breath. The following outcomes of physical fitness are obtained: peak oxygen uptake (peak VO2), peak heart rate and maximum heart rate at the anaerobic threshold. Anaerobic threshold are considered the mean value of 2 blinded investigators' independent readings. Considering that patients with pSS do not achieve a maximum effort, the anaerobic threshold is the main measure of aerobic fitness (VALIM et al, 2002; VALIM et al, 2003; ASSIS et al, 2006).
All the patients have been underwent an increasing load protocol on the treadmill, with a maximum duration of 13 minutes (VALIM et al, 2002; FAIRSHTER et al, 1983). Beginning with a warm-up period of 3 minutes at 3 km/h and increasing 1 km/h each minute until 7 km/h, at this moment 2,5% inclination is added until 15% in the 13º minute.
Measured: baseline and 16 weeks
Change from baseline in depression at 8 weeks
questionnaire: Beck Depression Inventory (BDI) (BECK et al, 1961; GORESTEIN and ANDRADE, 1996).
Measured: baseline and 8 weeks
Change from baseline in depression at 16 weeks
questionnaire: Beck Depression Inventory (BDI) (BECK et al, 1961; GORESTEIN and ANDRADE, 1996).
Measured: baseline and 16 weeks
Change from baseline in disease activity at 16 weeks
questionnaire: EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) (SEROR et al, 2010; SERRANO et al, 2013).
Measured: baseline and 16 weeks
Change from baseline in quality of life at 16 weeks
questionnaires: Medical Outcomes Study 36 (SF-36) (CICONELLI et al, 1999) and World Health Organization Quality of Life Instrument - Abbreviated version (WHOQOL-bref) (The Whoqol Group, 1998; FLERCK et al, 2000).
Measured: baseline and 16 weeks
Change from baseline in symptoms at 8 weeks
questionnaire: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) (SEROR et al, 2011, PAGANOTTI et al, 2012; PAGANOTTI et al, 2013).
Measured: baseline and 8 weeks
Change from baseline in symptoms at 16 weeks
questionnaire: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) (SEROR et al, 2011, PAGANOTTI et al, 2012; PAGANOTTI et al, 2013).
Measured: baseline and 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2015 (estimated)
- Study startMar 2015
- Primary completionDec 2015
- Study completionMar 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sjogren's SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samira Tatiyama Miyamoto, PhD
- Sponsor type
- University, hospital or other
- Collaborators
- Federal University of São Paulo, Newcastle University
- Responsible party
- Sponsor-investigator, Samira Tatiyama Miyamoto, PhD, Federal University of Espirito Santo
- Investigators
- Jamil Natour, PhD, Study chair, Universidade Federal de São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02370225
- Sponsor's protocol ID
- FUEspiritoSanto01
- Acronym
- AEPSS
- Status last verified
- Mar 2026
- First submitted
- 9 Feb 2015
- Last updated
- 23 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Miyamoto ST, Valim V, Carletti L, Ng WF, Perez AJ, Lendrem DW, Trennel M, Giovelli RA, Dias LH, Serrano EV, Subtil AM, Abreu VC, Natour J. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjogren's syndrome: a randomized-controlled trial. Rheumatol Int. 2019 Feb;39(2):227-238. doi: 10.1007/s00296-018-4213-z. Epub 2019 Jan 2.
PubMed 30604204
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Aerobic Exercise on Fatigue in Women With Primary Sjögren's Syndrome: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02370225
- Acronym / sponsor ID
- AEPSS / FUEspiritoSanto01
- Conditions
- Sjogren's Syndrome
- Keywords
- sjogren's syndrome, aerobic exercise, fatigue
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Samira Tatiyama Miyamoto, PhDUniversity, hospital or other
- Collaborators
- Federal University of São Paulo, Newcastle University
- Study start
- Mar 2015
- Primary completion
- Dec 2015 (actual)
- Study completion
- Mar 2016 (actual)
- First posted
- 24 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this sudy is to investigate the effects of a regular aerobic exercise on aerobic capacity, fatigue, depression, quality of life, perception of symptoms and disease activity in women with pSS.
Detailed description
This study is a randomized controlled trial. 45 women with primary Sjögren's syndrome diagnosed according to the American European Consensus Criteria (VITALI et al, 2002) and age ≤ 65 years-old will be included. Patients, in blocks of four, will be allocated to treatment group (TG) or control group (CG) by simple randomization according to drawing lots.
Treatment group (TG): subjects will be submitted to a supervised walking, 3 times a week for 16 weeks, by one physiotherapist and one physical education student who alternated weekly. The heart rate of the patients will be registered with a pulse watch (Polar® A1, Kempele, Finland) at the beginning, in the intermediate time and at the final of effective walking time. The general exertion was rated on the Borg RPE 0-10 (ratings of perceived exertion) scale in the intermediate time and at the final of effective walking time. Each training session will be preceded by a warm-up period, where patients will be instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they will be instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).
The exercise prescription will be based on the heart rate at the anaerobic threshold determined at the initial assessment according previous studies with patients with fibromyalgia (VALIM et al, 2002; VALIM et al, 2003; ASSIS et al, 2006) and Systemic Lupus Erythematosus (CARVALHO et al, 2005), which demonstrated that ventilatory anaerobic threshold oxygen uptake, although used less than VO2max, is also a good physical fitness indicator, and it has the advantage of not being maximum effort dependent. It seems to be more influenced by training than VO2max and represents a safer intensity for exercise, thus decreasing the risk of lesions and constituting an important measure for prescription of exercise. As there is no previous studies using spiroergometric test in pSS and fatigue is very similar to fibromyalgia and lupus patients, we believe pSS performance in treadmill test and training is probably the same. The increment of intensity exercise will be based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
Control group (CG): subjects randomized to control group will not participate of the walking exercise initially, but after completing 16 weeks they will be invited to participate of the training group.
Clinical outcomes:
- Fatigue: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) (WEBSTER et al, 1999; WEBSTER et al, 2003)
- Depression: Beck Depression Inventory (BDI) (BECK et al, 1961; GORESTEIN and ANDRADE, 1996).
- Perception of pSS's symptoms: EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) (SEROR et al, 2011, PAGANOTTI et al, 2012; PAGANOTTI et al, 2013).
- Disease activity: EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) (SEROR et al, 2010; SERRANO et al, 2013).
- Quality of life: Medical Outcomes Study 36 (SF-36) (CICONELLI et al, 1999) and World Health Organization Quality of Life Instrument - Abbreviated version (WHOQOL-bref) (The Whoqol Group, 1998; FLERCK et al, 2000).
- All patients will be submitted to interview to evaluate fatigue, depression and perception of pSS's symptoms prior to intervention (T0), after 8 weeks (T1) and after 16 weeks (T2). Quality of life and disease activity will be evaluated prior to intervention (T0) and after 16 weeks (T2). Patient global assessment of response to therapy (PGART) on a 5-point scale (1 _ much better, 2 _ better, 3 _ slightly better, 4 _ no change, and 5 _ worse).
Physical fitness outcomes:
Aerobic capacity will be evaluated by spiroergometric test. A computerized metabolic system is used to analyze the data obtained breath by breath. The following outcomes of physical fitness are obtained: peak oxygen uptake (peak VO2), peak heart rate and maximum heart rate at the anaerobic threshold. Anaerobic threshold are considered the mean value of 2 blinded investigators' independent readings. Considering that patients with pSS do not achieve a maximum effort, the anaerobic threshold is the main measure of aerobic fitness (VALIM et al, 2002; VALIM et al, 2003; ASSIS et al, 2006).
All the patients will be underwent an increasing load protocol on the treadmill, with a maximum duration of 13 minutes (VALIM et al, 2002; FAIRSHTER et al, 1983). Beginning with a warm-up period of 3 minutes at 3 km/h and increasing 1 km/h each minute until 7 km/h, at this moment 2,5% inclination is added until 15% in the 13º minute.
All patients will be evaluated prior to intervention (T0) and after 16 weeks (T2).
Statistics:
An intent-to-treat analysis will be performed, using the last-observation-carried-forward method. A level of significance of P<0.05 (2-tailed tests) will be accepted for the trial. The Kolmogorov-Smirnov test will be used to determine whether data will be normally or non-normally distributed. For normally distributed data, the dependent variables will be analyzed using a 2 per 3 repeated-measures analysis of variance (ANOVA). The independent variables in all analyses is group (TG versus CG; between subjects factors) and time (baseline, 8 weeks, and 16 weeks; within subjects factors). Independent sample t-tests will be used in the between-groups comparison of the change scores at midline and treatment completion, when interaction time x group was significant. A 95% confidence interval (95% CI) will be used. Friedman's test will be used for non-normally distributed variables, as an equivalent of ANOVA. Wilcoxon's signed rank test will be used to analyze the difference between times separated by group when the change score was non-normally distributed. Fisher's exact test and chisquare test will be used to determine differences in rates of improvement between the 2 groups. Pearson's and Spearman's correlation coefficients will be used. Multiple linear regression and chi-square tests will be used to analyze the association between the amount of physical fitness improvement and outcome measures. The agreement between heart rate and ratings of perceived exertion during the training will be analyzed by Intraclass Correlation Coefficient.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| aerobic exercise | Experimental | Other: aerobic exerciseSubjects were submitted to a supervised walking, 3 times a week for 16 weeks. |
| no exercise | No intervention | –Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- female gender and age ≤ 65 years-old
- pSS diagnosed according to the American European Consensus Criteria (VITALI et al, 2002)
- corporal mass index < 40.
Key exclusion criteria (4 listed)
- use of beta-blocker therapy;
- severe manifestations on pulmonary, renal, neurologic or musculoskeletal system (from the disease or not);
- limiting or hindering their ability to walking performance
- those who had performed regular physical activity in the 6 weeks before trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| aerobic exerciseEach training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period). The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end. | Other | aerobic exercise |
Primary outcome
Change from baseline in fatigue at 16 weeks
Time frame: baseline and 16 weeks
questionnaires: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) (WEBSTER et al, 1999; WEBSTER et al, 2003)
7 secondary outcomes
Change from baseline in aerobic capacity at 16 weeks
Time frame: baseline and 16 weeks
Change from baseline in depression at 8 weeks
Time frame: baseline and 8 weeks
Change from baseline in depression at 16 weeks
Time frame: baseline and 16 weeks
Change from baseline in disease activity at 16 weeks
Time frame: baseline and 16 weeks
Change from baseline in quality of life at 16 weeks
Time frame: baseline and 16 weeks
Change from baseline in symptoms at 8 weeks
Time frame: baseline and 8 weeks
Change from baseline in symptoms at 16 weeks
Time frame: baseline and 16 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2026.
- Derived from this study: PubMed 30604204Miyamoto ST, Valim V, Carletti L, Ng WF, Perez AJ, Lendrem DW, Trennel M, Giovelli RA, Dias LH, Serrano EV, Subtil AM, Abreu VC, Natour J. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjogren's syndrome: a randomized-controlled trial. Rheumatol Int. 2019 Feb;39(2):227-238. doi: 10.1007/s00296-018-4213-z. Epub 2019 Jan 2.
- Individual participant dataSharing planned: Undecided
Related trials for Sjogren's Syndrome
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Recruiting
Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary Sjögren's Syndrome
Sjögren's Syndrome, Small Fiber Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jamil Natour, PhD study chair
Universidade Federal de São Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing aerobic exercise in people with Sjogren's Syndrome, run by Samira Tatiyama Miyamoto, PhD at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in fatigue at 16 weeks (time frame: baseline and 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02370225, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2026.